Jefferies Initiates Coverage On LeMaitre Vascular with Buy Rating, Announces Price Target of $70
Jefferies analyst Anthony Petrone initiates coverage on LeMaitre Vascular (NASDAQ:LMAT) with a Buy rating and announces Price Target of $70.
Roth Capital Maintains Neutral on LeMaitre Vascular, Raises Price Target to $58
Roth Capital analyst Scott Henry maintains LeMaitre Vascular (NASDAQ:LMAT) with a Neutral and raises the price target from $55 to $58.
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell
• Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.
55 Biggest Movers From Yesterday
Gainers
SGOCO Group, Ltd. (NASDAQ: SGOC) shares gained 37.6% to settle at $13.20 on Wednesday. SGOCO Group regained compliance with Nasdaq's listing standards on July 12 by filing its FY20 20-F.
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy’s Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 21)
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira’s CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)